Clinical trials: in Austria
Bipolar 1 Disorder, Control Subjects
Socio-cognitive and Biological Responses to Maltreatment
The study will investigate how a history of emotional childhood maltreatment (CM) is associated with different aspects of psychological (social behaviour, empathy) and biological (brain function and structure, inflammation)…
- Trial name
- NCT07101107
- Where
- Austria
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals
Obesity
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy"…
- Trial name
- STEP Young (NCT05726227)
- Testing
- Semaglutide
- Where
- 56 sites in United States, Austria and 8 more
- Volunteers
- 212 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Multiple Myeloma
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide…
- Trial name
- MajesTEC-4 (NCT05243797)
- Testing
- Teclistamab, Lenalidomide
- Where
- 212 sites in United States, Argentina and 23 more
- Volunteers
- 1,594 people
- Sponsor
- European Myeloma Network B.V.
ECT, Depression
Comparison of Esketamine/Propofol and Methohexital Anesthesia for ECT
The current anesthetic drug used as standard for ECT procedure at the Department of Psychiatry and Psychotherapy, Medical University of Vienna, is the barbiturate methohexital (Brevital®).
- Trial name
- Ketofol (NCT05655754)
- Testing
- Methohexital, Ketofol
- Where
- Austria
- Volunteers
- 56 people
- Sponsor
- Medical University of Vienna
Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention.
- Trial name
- AMAY (NCT05509777)
- Testing
- Mirikizumab
- Where
- 81 sites in United States, Austria and 14 more
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Immune Thrombocytopenia
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in…
- Trial name
- LUNA 3 (NCT04562766)
- Testing
- Rilzabrutinib
- Where
- 155 sites in United States, Argentina and 24 more
- Volunteers
- 232 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Diabetes Mellitus, Obesity
Multinational Point Prevalence Study on the Management of Diabesity in Hospitals
Diabetes related to obesity ("diabesity") is becoming increasingly prevalent. Hospitalizations among people with diabetes are frequent and glycaemic control is often suboptimal during these stays.
- Trial name
- DiabesityDay (NCT06680674)
- Testing
- Routine care for people with diabetes, with or without obesity, in the hospital setting
- Where
- 8 sites in Austria, Czechia and 6 more
- Volunteers
- 207 people
- Sponsor
- Medical University of Vienna
IDH-mutant Grade 2 or 3 Astrocytoma
Vorasidenib Maintenance for IDH Mutant Astrocytoma
The main goal of VIGOR is to demonstrate that vorasidenib maintenance therapy improves locally assessed progression-free survival (PFS) from enrolment compared to placebo in patients with IDH-mutant, CNS5 WHO Grade 2 or 3…
- Trial name
- VIGOR (NCT06809322)
- Testing
- Vorasidenib
- Where
- 59 sites in Australia, Austria and 10 more
- Volunteers
- 468 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Follicular Lymphoma (FL)
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).
- Trial name
- OLYMPIA-1 (NCT06091254)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 190 sites in United States, Australia and 17 more
- Volunteers
- 822 people
- Sponsor
- Regeneron Pharmaceuticals
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
- Trial name
- ARCHER II (NCT06510816)
- Testing
- Vonaprument
- Where
- 132 sites in United States, Australia and 12 more
- Volunteers
- 659 people
- Sponsor
- Annexon, Inc.
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Crohn Disease, Colitis, Ulcerative
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
The primary objective of the study is to evaluate the efficacy of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 4 weeks (Q4W) in adult participants with inflammatory bowel disease (IBD).
- Trial name
- NCT05668013
- Testing
- TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
- Where
- 93 sites in United States, Austria and 14 more
- Volunteers
- 247 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Locally Advanced or Metastatic Renal Cell Carcinoma
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after…
- Trial name
- CaboPoint (NCT03945773)
- Testing
- Cabozantinib
- Where
- 40 sites in Austria, France and 5 more
- Volunteers
- 127 people
- Sponsor
- Ipsen
Advanced Parkinson Disease
Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
This observational study is designed to collect data on the use of the drug Lecigon® in daily clinical practice. The study is organised and funded by a pharmaceutical company called Britannia Pharmaceuticals Ltd (Britannia).
- Trial name
- ELEGANCE (NCT05043103)
- Testing
- Lecigon® based on European Medicines Agency (EMA) SmPC
- Where
- 57 sites in Austria, Belgium and 12 more
- Volunteers
- 312 people
- Sponsor
- Britannia Pharmaceuticals Ltd.
Neonate, Sepsis
Point of Care - Sepsis Study
This pilot study will evaluate whether a rapid point-of-care blood test can help identify early signs of infection and sepsis in preterm infants.
- Conditions
- Neonate, Sepsis, IL6, PCT
- Trial name
- POCT Sepsis (NCT07774013)
- Testing
- Point-of-Care Measurement of Inflammatory Biomarkers
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Medical University of Graz
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Rheumatoid Arthritis
MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis
The MethMax trial is a prospective, international, multicentre, randomised, assessor-blinded, parallel-group, low intervention study.
- Trial name
- MethMax (NCT06649136)
- Testing
- Methotrexate
- Where
- Austria
- Volunteers
- 182 people
- Sponsor
- Medical University of Vienna
Short Stature Children Born Small for Gestational Age (SGA)
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already…
- Trial name
- NCT03878446
- Testing
- Somapacitan, Norditropin®
- Where
- 95 sites in United States, Algeria and 21 more
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.